Interleukin-1 Regulates Multiple Atherogenic Mechanisms in Response to Fat Feeding
暂无分享,去创建一个
Gary Shaw | Nicholas J. Alp | N. Alp | D. Crossman | S. Francis | S. Dower | D. Graham | Delyth Graham | J. Chamberlain | Janet Chamberlain | Sheila Francis | Zoe Brookes | Steven Dower | David C. Crossman | Z. Brookes | G. Shaw
[1] R. de Caterina,et al. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[2] A. Kenny,et al. The role of fish oil in hypertension. , 2007, Connecticut medicine.
[3] K. Kondo,et al. Antihypertensive effect and safety of dietary alpha-linolenic acid in subjects with high-normal blood pressure and mild hypertension. , 2007, Journal of oleo science.
[4] G. Dusting,et al. The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. , 2005, Cardiovascular research.
[5] K. Krause,et al. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. , 2007, Physiological reviews.
[6] P. Andrew,et al. Guanylyl cyclase mediates ANP-induced vasoconstriction of murine splenic vessels. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.
[7] G. Biondi-Zoccai,et al. Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction , 2008, Circulation.
[8] R. Turner,et al. Interleukin-1 and Nitric Oxide Increase NADPH Oxidase Activity in Human Coronary Artery Smooth Muscle Cells , 2003, Medical Principles and Practice.
[9] D. Crossman,et al. Interleukin-1 Receptor Antagonist Expression in Human Endothelial Cells and Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[10] D. Harrison,et al. Coronary Artery Superoxide Production and Nox Isoform Expression in Human Coronary Artery Disease , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[11] Y. Sharabi,et al. Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. , 2007, Atherosclerosis.
[12] K. Reue,et al. Cholesterol and Cholate Components of an Atherogenic Diet Induce Distinct Stages of Hepatic Inflammatory Gene Expression* , 2003, Journal of Biological Chemistry.
[13] P. Young,et al. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[14] Christopher K. Glass,et al. Atherosclerosis The Road Ahead , 2001, Cell.
[15] J. Lekakis,et al. Inhibition of Interleukin-1 by Anakinra Improves Vascular and Left Ventricular Function in Patients With Rheumatoid Arthritis , 2008, Circulation.
[16] K. Tezuka,et al. Interleukin-1beta induces tissue- and cell type-specific expression of adhesion molecules in vivo. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[17] A. Vollmer,et al. High-fat diet elevates blood pressure and cerebrovascular muscle Ca(2+) current. , 2000, Hypertension.
[18] R. de Caterina,et al. The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKCε inhibition , 2006, Proceedings of the National Academy of Sciences.
[19] D. Harrison,et al. Endothelial Regulation of Vasomotion in ApoE-Deficient Mice: Implications for Interactions Between Peroxynitrite and Tetrahydrobiopterin , 2001, Circulation.
[20] K. Rockett,et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. , 2003, The Journal of clinical investigation.
[21] G. Getz,et al. Diet and Murine Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[22] A. Vollmer,et al. High-Fat Diet Elevates Blood Pressure and Cerebrovascular Muscle Ca2+ Current , 2000 .
[23] N. Camp,et al. Genetic variation at the interleukin-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes. , 2002, Clinical science.
[24] Bryan Williams,et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials , 2006, Journal of hypertension.
[25] S. Kaufman,et al. Myogenic responses and compliance of mesenteric and splenic vasculature in the rat. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.
[26] J. Arnal,et al. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. , 1998, Circulation.
[27] B. Rosner,et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. , 2005, JAMA.
[28] A. Mantovani,et al. The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. , 1994, Immunology today.
[29] R. Cotran,et al. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells , 1984, The Journal of experimental medicine.
[30] David Evans,et al. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. , 2006, The American journal of pathology.
[31] M. Seishima,et al. Lack of Interleukin-1&bgr; Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[32] C. Devlin,et al. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[33] R. Levine,et al. Interleukin-1 Receptor Signaling Mediates Atherosclerosis Associated With Bacterial Exposure and/or a High-Fat Diet in a Murine Apolipoprotein E Heterozygote Model: Pharmacotherapeutic Implications , 2004, Circulation.
[34] S. Malozowski,et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.
[35] N. Alp,et al. Increased Endothelial Tetrahydrobiopterin Synthesis by Targeted Transgenic GTP-Cyclohydrolase I Overexpression Reduces Endothelial Dysfunction and Atherosclerosis in ApoE-Knockout Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[36] F. Ohsuzu,et al. Lack of Interleukin-1 Receptor Antagonist Modulates Plaque Composition in Apolipoprotein E–Deficient Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[37] Jiqiu Chen,et al. Hypertension Does Not Account for the Accelerated Atherosclerosis and Development of Aneurysms in Male Apolipoprotein E/Endothelial Nitric Oxide Synthase Double Knockout Mice , 2001, Circulation.
[38] C. Holt,et al. Interleukin-1β in Coronary Arteries of Patients With Ischemic Heart Disease , 1996 .
[39] J. Gunn,et al. Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model. , 2005, Cardiovascular research.
[40] F. Sacks,et al. Does Fish Oil Lower Blood Pressure? A Meta‐Analysis of Controlled Trials , 1993, Circulation.
[41] P. Libby,et al. Inducible interleukin-1 gene expression in human vascular smooth muscle cells. , 1986, The Journal of clinical investigation.